Home / Inspections / 1116333

FDA Inspection 1116333 — Halo Pharmaceutical, Inc. d/b/a Cambrex Whippany

Halo Pharmaceutical, Inc. d/b/a Cambrex Whippany — FEI 2211084

The FDA completed an inspection of Halo Pharmaceutical, Inc. d/b/a Cambrex Whippany on December 20, 2019 in Whippany, NJ. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
December 20, 2019
Fiscal Year
2020
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Whippany, NJ (United States)

Facility

Other inspections at this facility

  • 1297650 (NAI Mon Dec 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1197680 (NAI Fri Feb 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1055544 (VAI Wed May 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1027562 (NAI Thu Aug 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1008344 (VAI Mon Mar 20 2017 00:00:00 GMT+0000 (Coordinated Universal Time))

FDA data resources